TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Botswana TDF/FTC Oral HIV Prophylaxis Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* citizen of Botswana 18-39 years old~* sexually active~* HIV uninfected~* Hepatitis B and C uninfected~* Calculated creatinine clearance \>= 60 mL/min~* hemoglobin \>= 8 gm/dL~* ALT and AST \<= 2x ULN~* total bilirubin \<= 1.5 mg/dL~* total serum amylase \<= 1.5x ULN~* Serum phosphorus \>= 2.2 mg/dL~* willing to use hormonal contraception (females)~* living within 1 hours travel of study clinic~* pass comprehension test~* willing and able to give informed consent~Exclusion Criteria:~* 18-20 without parent/guardian consent~* history of significant renal or bone disease~* any chronic illness requiring ongoing prescription medication~* pregnant or breastfeeding~* planning to move away from site in the next year~* participating in another HIV prevention or vaccine safety trial~* any other clinical condition or prior therapy that, in the opinion of the study physician, would make the volunteer unsuitable for the study or unable to comply with the dosing requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: t

Study Arms:
- TDF-FTC,condoms,adh/risk counseling (Type: ACTIVE_COMPARATOR): Eligible participants were randomized to oral Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg (TDF-FTC) once daily in the form of a single tablet. The ratio of randomization was 1:1. Participants randomized to the active arm received male and female condoms, risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.
- Placebo,condoms,adh/risk counseling (Type: PLACEBO_COMPARATOR): Eligible participants were randomized to the placebo arm and received placebo oral tablets that were visually identical to the TDF-FTC tablet and taken once daily. The placebo tablets contained no active ingredients. The ratio of randomization was 1:1. Participants randomized to the placebo arm received male and female condoms, personalized risk reduction counseling, adherence counseling, and routine monitoring for HIV infection, laboratory abnormalities, and adverse events.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Diagnosis of Androgenetic Alopecia / Female Pattern Hair Loss Fitzpatrick skin phototypes of I - IV Ludwig-Savin Hair Loss scale I - II In overall good health as determined by the physician investigator Active hair loss within the last 12 months Willingness to refrain from using all other hair growth products or treatments -~Exclusion Criteria:~Photosensitivity to the specific wavelength of light - 650 nanometers. Malignancy in the target treatment area Other forms of alopecia of the head Past medical history of a collagen-vascular disease, thyroid disease or other cutaneous or systemic disease that seriously affects the scalp.~In willingness to remove hair replacement products during the 16 weeks of therapy.~Using any medications deemed to inhibit hair growth as determined by the physician investigator.~-

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Incandescent red light source (Type: PLACEBO_COMPARATOR): A red, incandescent light source replaces all laser output. The treatment sessions are self-administered at home, every other day, for 16 weeks.
- Handi-Dome Laser (Type: ACTIVE_COMPARATOR): Study subjects self-administer actual laser treatments, at home, every other day, for 16 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is postmenopausal.~* Subject has moderate to severe vaginal dryness as the self-reported MBS of VVA.~Exclusion Criteria:~* Subject has clinically significant abnormal findings in the physical examination.~* Subject has a body mass index (BMI) equal to or greater than 38 kg/m\^2~* Subject has uncontrolled hypertension.~* Subject has clinically significant abnormal findings in the gynecological examination other than signs of vaginal atrophy.~* Subject has uterine/vaginal bleeding of unknown origin.~* Subject has a vaginal infection requiring medication (may be treated and be eligible for study).

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ospemifene (Type: EXPERIMENTAL): Participants will take one tablet of ospemifene 60 mg orally, once a day for 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants will take one tablet of matching placebo, orally, once a day for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Effectiveness and Safety of Paliperidone ER (Extended-release) Compared With Quetiapine in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual - Fourth Edition (DSM-IV) diagnosis of schizophrenia (paranoid, disorganized or undifferentiated type)~* score of \>=4 on at least two of a subset of selected PANSS items and a total score on these five items of \>=17~* score of \>=5 on the CGI-S (clinical global impression - severity)~* body weight of at least 60kg and willing to be hospitalized for 9 days initially~Exclusion Criteria:~* A primary active mental illness diagnosis other than schizophrenia~* subjects whose psychotic symptoms can be explained by substance intake or medical illness~* pregnancy, breast-feeding, or planning to become pregnant~* a history of treatment resistance (defined by failure to respond to 2 adequate trials of different antipsychotic medications or clozapine given at adequate dose for sufficient time)~* unstable or significant medical illness that would increase risk of taking study medication or would confuse the interpretation of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged 18-75 years (both inclusive) at the time of signing informed consent~* Diagnosed with type 2 diabetes mellitus greater than or equal to 180 days prior to the day of screening~* HbA1c of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory~* Stable daily dose(s) for 90 days prior to the day of screening of any of the following antidiabetic drug(s) or combination regime(s):~  1. Any metformin formulations greater than or equal to 1500 mg or maximum tolerated or effective dose (as documented in subject's medical records)~ 2. Free or fixed combination therapy: Metformin as outlined above plus/minus DPP4i with or without SGLT2i is allowed:~  i) DPP4i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose) ii) SGLT2i (greater than or equal to half of the maximum approved dose according to local label or maximum tolerated or effective dose )~* Insulin-naïve. However, short term insulin treatment for a maximum of 14 days prior to the day of screening is allowed, as is prior insulin treatment for gestational diabetes~* Body mass index (BMI) below or equal to 40.0 kg/m\^2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin 287 algorithm A (Type: EXPERIMENTAL): Controlled on metformin with or without DPP4i (dipeptidyl peptidase-4 inhibitors) and with or without SGLT2i (sodium-glucose cotransporter 2 inhibitors).
- Insulin 287 algorithm B (Type: EXPERIMENTAL): Controlled on metformin with or without DPP4i and with or without SGLT2i.
- Insulin 287 algorithm C (Type: EXPERIMENTAL): Controlled on metformin with or without DPP4i and with or without SGLT2i.
- Insulin Glargine algorithm D (Type: ACTIVE_COMPARATOR): Controlled on metformin with or without DPP4i and with or without SGLT2i.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 or older who received a lung or heart/lung transplant from January 1, 2002 through December 31, 2009 in the MarketScan database will be initially included in the study.~Exclusion Criteria:~* Patients who are younger than 18 years of age and who are not enrolled for at least 180 days before and 180 days after the date of transplant will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Any Voriconazole (Type: None): None
- No Voriconazole (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria;~-Proton pump inhibitor-resistant reflux esophagitis. (Patients who have mucosal breaks (erosions, ulcers) on endoscopy)~Exclusion criteria;~* Patients with a history of hypersensitivity to any ingredients of PARIET.~* Patients on atazanavir sulfate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rabeprazole Sodium (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~1. Type 2 diabetes~2. Elevated glycosylated haemoglobin (HbA1c): 6.5 - 8.5%, inclusive, if treatment naïve or mono-/dual therapy with metformin and/or an alpha-glucosidase inhibitor; 6.5 - 7.5%, inclusive, if treatment with sulphonylurea/glinide in mono- or dual (with metformin OR an alpha-glucosidase inhibitor) therapy)~3. Pre-existing cardiovascular disease OR specified diabetes end-organ damage OR age =\> 70 years OR two or more specified cardiovascular risk factor~4. BMI =\< 45kg/m²~5. age between \>= 40 and =\< 85 years~6. signed and dated written International Conference of Harmonisation( ICF)~7. stable anti-diabetic background for at least 8 wks before study start~Exclusion criteria:~1. Type 1 diabetes~2. Treatment with other antidiabetic drugs (e.g. rosiglitazone, pioglitazone, Glucagon-like peptide 1 (GLP-1) analogue/agonists, Dipeptidyl-peptidase IV (DPP-IV) inhibitors or any insulin) prior to informed consent (previous short term use of insulin (up to two weeks) is allowed if taken at least 8 weeks prior informed consent)~3. treatment with any anti-obesity drug less than 3 months before ICF~4. uncontrolled hyperglycemia~5. previous or planned bariatric surgery or intervention~6. current or planned system corticoid treatment~7. change in thyroid hormones treatment~8. acute liver disease or impaired hepatic function~9. pre-planned coronary artery revascularization within 6 months of ICF~10. known hypersensitivity to any of the components~11. Inappropriateness of glimepiride treatment for renal safety issues according to local prescribing information~12. congestive heart failure class III or IV~13. acute or chronic metabolic acidosis~14. hereditary galactose intolerance~15. alcohol or drug abuse~16. participation in another trail with IMP given 2 months before Investigational Medicinal/Medical Product (IMP) start~17. pre-menopausal women who are nursing or pregnant or of child-bearing potential and not willing to use acceptable method of birth control~18. patients considered reliable by the investigator~19. acute coronary syndrome =\< 6 wks before ICF~20. stroke or Transient Ischemic Attack (TIA) =\< 3 months prior to ICF

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- linagliptin (Type: EXPERIMENTAL): patient to receive linagliptin or glimepiride placebo over encapsulated tablet Quaque die (QD)
- glimepiride 1-4 mg QD (Type: ACTIVE_COMPARATOR): patient to receive glimepiride 1-4 mg or linagliptin placebo tablet Quaque die (QD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has ceased lactating or agrees not to provide breastmilk to her infant(s) from just prior to receiving the investigational product (IP) on Day 1 until 7 days after the last dose of IP.~* Participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Diagnostic and DSM-5 Clinical Trial Version (SCID-5-CT).~* Participant is ≤12 months postpartum at screening and Day 1.~Exclusion Criteria:~* Participant is at significant risk of suicide or has attempted suicide associated with the current episode of PPD.~* Participant has active psychosis per investigator assessment.~* Participant has a medical history of nonfebrile seizures.~* Participant has a medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.~* Participant has a history of sleep apnea.~Note: Other protocol-defined inclusion/exclusion criteria applied.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received SAGE-217 matched-placebo capsules, orally, once daily for 14 days.
- SAGE-217 50 mg (Type: EXPERIMENTAL): Participants received SAGE-217, 50 mg, capsules, orally, once daily for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 21 - 65 years old at time of screening visit. Both genders and any race will be accepted.~* Diagnosis of BPD I or II without significant co-morbid secondary medical or psychiatric diagnoses; no substance abuse or dependence during preceding 12 months~* A minimum score of 18 on the first 17 items of the 21-item Hamilton Depression Scale~* Willingness to washout for a reasonable time (depending on the substance) from: Vitamin E and fish oils (\>600 IU/day), non-aspirin NSAIDs or aspirin (\>81 mg/day, H2 receptor antagonists, Ginko biloba, caffeine on morning of blood drawing, and to institute lights-out at 23:00 hours on the nights before blood drawings~Exclusion Criteria:~* Any abnormal findings on the physical exam, ECG, blood/urine or minor infections~* Any pre-existing physical pain condition, including fibromyalgia~* History of peptic ulcer complicated by perforation, hemorrhage, or obstruction; symptoms of peptic ulcer within 4 weeks of enrollment date~* Any substance abuse or dependence during the preceding 12 months~* Clinically significant hypertension, anemia, liver disease, kidney disease, arthritis, diabetes, recurrent migraines, epilepsy, stroke, gum disease, autoimmune disease~* Current use of lithium~* Current use of a stimulant~* Certain steroids including use of hormonal birth control and any systemic or topical corticosteroids (hormone replacement therapy will be allowed)~* Unwillingness to refrain from H2 receptor antagonists, non-aspirin NSAIDs, or aspirin (more than 1 mg/day).~* Use of any anticoagulant agents~* Use of nicotine-containing substances. Subjects who quit smoking more than 3 months prior to assessment may be considered for the study~* Known sensitivity or allergy to the study medications or a need to receive agents that are contra-indicated in combination with CBX or ESC~* Unwillingness to fast and abstain from caffeine on mornings of blood drawings~* A sleep disorder other than insomnia or hypersomnia as a distinct symptom of major depressive disorder (MDD)~* Inability to commit to the follow-up visits between 8 and 11 am

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Intervention cohort (Type: EXPERIMENTAL): Participants assigned to the intervention cohort receive 10mg escitalopram twice daily plus 200mg celecoxib twice daily.
- Control cohort (Type: PLACEBO_COMPARATOR): Participants assigned to the control cohort receive 10mg escitalopram twice daily plus placebo administered twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed locally advanced rectal cancer;~2. 18-70 years ；~3. Clinicalstage:T3,4a,N0,M0;T1-4a,N+,M0;~4. Tumor from anus \>5cm and ≤15cm;~5. ECOG=0-1;~6. Available organ function:ALT≤1.5xULN;AST≤1.5xULN;TBIL≤1.0xULN; NEUT≥2×109/L;PLT≥100×109/L;Hb≥90g/L;Creatinine≤1.0xULN;~7. Informed consent;~8. UGT1A1:UGT1A1\*1/UGT1A1\*1,UGT1A1\*1/UGT1A1\*28,UGT1A1\*1/UGT1A1\*6;~Exclusion Criteria:~1. Clinical stage T4b or unresectable disease;~2. History of pelvic radiotherapy;~3. History of chemotherapy within 5 years;~4. History of chronic diarrhea;~5. Tumor causes intestinal obstruction, intestinal perforation, and severe bleeding;~6. Hepatitis B surface antigen positive; Hepatitis C virus infection; Cirrhosis of the liver for any cause;~7. UGT1A1:UGT1A1\*28/UGT1A1\*28,UGT1A1\*6/UGT1A1\*6;~8. Other cancers in the past 5 years, except for cervical carcinoma in situ or non-melanoma skin cancer;~9. Myocardial infarction (in the last 6 months), severe instability angina, congestive heart failure; interstitial pneumonia,pulmonary fibrosis, uncontrolled diabetes, renal insufficiency;~10. Mental illness;Pregnant or lactating women;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- FOLFOXIRI (Type: EXPERIMENTAL): oxaliplatin 85 mg/m2 irinotecan 150 mg/m2, 5FU 2,400 mg/m2 by 46 h infusion repeated at 2week intervals

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, ages 18 years or older who have signed the informed consent~* Has a qualifying skin and skin structure infection~* Female patients must not be pregnant at the time of enrollment~* Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug~Exclusion Criteria:~* Infections where the outcome is strongly influenced by factors other than protocol-defined treatments and procedures, or that require antibacterial treatment for greater than 14 days~* Evidence of significant immunological disease~* Severe renal disease or requirement for dialysis~* Evidence of septic shock~* Has a history of hypersensitivity or allergic reaction to any tetracycline or to linezolid~* Has received an investigational drug within the past 30 days~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omadacycline (Type: EXPERIMENTAL): Omadacycline tablets
- Linezolid (Type: ACTIVE_COMPARATOR): Linezolid tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete